UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,537 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 6.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,193 shares of the company’s stock after selling 4,537 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.06% of Day One Biopharmaceuticals worth $908,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after buying an additional 1,002 shares during the period. Quest Partners LLC lifted its position in Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after acquiring an additional 7,668 shares during the last quarter. SG Americas Securities LLC bought a new stake in Day One Biopharmaceuticals during the second quarter valued at about $113,000. Point72 DIFC Ltd acquired a new stake in shares of Day One Biopharmaceuticals in the second quarter valued at about $124,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Day One Biopharmaceuticals in the second quarter valued at about $163,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. Finally, Needham & Company LLC restated a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $35.71.

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the sale, the insider now owns 1,034,015 shares of the company’s stock, valued at $13,762,739.65. The trade was a 2.82 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 51,745 shares of company stock valued at $748,567 over the last quarter. Corporate insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Trading Down 0.6 %

DAWN opened at $12.46 on Friday. The stock’s 50 day simple moving average is $14.09 and its 200-day simple moving average is $14.01. The stock has a market cap of $1.26 billion, a PE ratio of -12.10 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 1 year low of $11.94 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same period last year, the firm earned ($0.54) EPS. Equities analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.